KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer
After platinum chemotherapy, the combination of the kinase inhibitor lenvatinib and pembrolizumab lengthened survival compared with doxorubicin or paclitaxel in advanced endometrial cancer, including in the mismatch repair-proficient majority.
Overview
Phase 3 trial of 827 patients with advanced endometrial cancer after one prior platinum regimen randomised to lenvatinib plus pembrolizumab or physician's choice of doxorubicin or weekly paclitaxel.
In mismatch repair-proficient disease median overall survival was 17.4 versus 12.0 months (hazard ratio 0.68) and median progression-free survival 6.6 versus 3.8 months; results were similar in the whole population. Grade 3 or higher adverse events occurred in 89 percent of the combination arm.
- Mismatch repair-proficient: median overall survival 17.4 vs 12.0 months; hazard ratio 0.68.
- All patients: median overall survival 18.3 vs 11.4 months; hazard ratio 0.62.
Lenvatinib-pembrolizumab is the standard second-line treatment for mismatch repair-proficient endometrial cancer after platinum, though its toxicity is considerable and its place after first-line immunotherapy is unclear.
- Hypertension, hypothyroidism, diarrhoea and weight loss led to frequent dose reductions.
- Patients had not received prior immunotherapy, unlike many today.
Similar pages
not linked directly; found by shared links- PairingLenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)
Shares KEYNOTE-775 / Study 309, Lenvatinib, Pembrolizumab.
- Key paperNRG-GY018: pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer
Shares Advanced or recurrent endometrial cancer, New England Journal of Medicine, Pembrolizumab.
- TrialLEAP-002
Shares Lenvatinib, Pembrolizumab.
- TrialPembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge
Shares Lenvatinib, Pembrolizumab.
- Key paperKEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma
- TrialLITESPARK-012
Shares Lenvatinib, Pembrolizumab.
- TrialStudy of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Shares Advanced or recurrent endometrial cancer, Lenvatinib.
- TrialPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Shares Lenvatinib, Pembrolizumab.